# A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Source: https://onco.cc/trials/nct02332668/  
OnCo record `nct02332668` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in melanoma and hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) is a phase 1/2 interventional study registered as NCT02332668 by Merck Sharp & Dohme LLC, with 370 participants planned, started 2015-03-19 and due to reach its primary completion in 2028-02-02. Interventions recorded: Pembrolizumab. Conditions listed: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02332668
- Phase: 1/2
- Setting: A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 370

## Sources

- ClinicalTrials.gov NCT02332668: https://clinicaltrials.gov/study/NCT02332668

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct02332668.json